You are here

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.

TitleMaraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
Publication TypeJournal Article
Year of Publication2010
AuthorsCooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, Clumeck N, Walmsley S, Ting N, Coakley E, Reeves JD, Reyes-Teran G, Westby M, van der Ryst E, Ive P, Mohapi L, Mingrone H, Horban A, Hackman F, Sullivan J, Mayer H
JournalJ Infect Dis
Volume201
Issue6
Pagination803-13
Date Published2010 Mar 15
ISSN1537-6613
KeywordsAdolescent, Adult, Aged, Anti-HIV Agents, Anti-Retroviral Agents, Antiviral Agents, Benzoxazines, CCR5 Receptor Antagonists, Cyclohexanes, Double-Blind Method, Drug Combinations, Drug Resistance, Viral, Drug Therapy, Combination, Female, HIV Infections, HIV-1, Humans, Lamivudine, Male, Middle Aged, Receptors, CCR5, Treatment Outcome, Triazoles, Viral Load, Viral Tropism, Young Adult, Zidovudine
Abstract

BACKGROUND: The MERIT (Maraviroc versus Efavirenz in Treatment-Naive Patients) study compared maraviroc and efavirenz, both with zidovudine-lamivudine, in antiretroviral-naive patients with R5 human immunodeficiency virus type 1 (HIV-1) infection.

METHODS: Patients screened for R5 HIV-1 were randomized to receive efavirenz (600 mg once daily) or maraviroc (300 mg once or twice daily) with zidovudine-lamivudine. Coprimary end points were proportions of patients with a viral load

RESULTS: The once-daily maraviroc arm was discontinued for not meeting prespecified noninferiority criteria. In the primary 48-week analysis (n = 721), maraviroc was noninferior for

CONCLUSIONS: Twice-daily maraviroc was not noninferior to efavirenz at

DOI10.1086/650697
Alternate JournalJ. Infect. Dis.
PubMed ID20151839